MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline
The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.
You may also be interested in...
AstraZeneca Silent On Pfizer, Uses Growth And Pipeline To Speak For Its Prospects
AstraZeneca played it straight when reporting a strong second quarter, outlining a robust late stage pipeline, a growing list of early assets and collaborations, while avoiding “the elephant in the room” - predator Pfizer’s paused-pursuit of the U.K. pharma.
“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader
Though AstraZeneca is in several ways playing catch up in the oncology space, a strategy built around speed, differentiation and carving out areas of leadership has the firm poised for transformation. Execs are particularly confident the company will become a dominant force as combinations become a larger part of cancer care, pulling from its immunotherapeutic and small molecule pipelines.
AstraZeneca Playing Leapfrog In Immunotherapy: How It Plans To Lead From Behind
AstraZeneca has not been at the front of the PD-1/L1 immune checkpoint inhibitor race, but execs explain how the company is making strategic choices in immuno-oncology to make it first to the finish line in unique areas.